{"disease":{"id":"irritable-bowel","name":"irritable bowel"},"drugs":{"marketed":[{"drug_id":"rifaximin","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xifaxan","generic_name":"rifaximin","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":"1500","mechanism":null},{"drug_id":"tenapanor","indication_name":"Irritable Bowel Syndrome with Constipation (IBS-C)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TENAPANOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"mebeverine","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEBEVERINE","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"mebeverine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd1722","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibsrela","generic_name":"AZD1722","company_name":"Ardelyx Inc","drug_phase":"marketed","molecular_target":"Sodium/hydrogen exchanger 3","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibsrela works by inhibiting the sodium/hydrogen exchanger 3, a protein that regulates the balance of sodium and hydrogen ions in the gut."},{"drug_id":"eluxadoline","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viberzi","generic_name":"ELUXADOLINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"mu-Opioid Receptor Agonist [EPC]","quality_score":48,"revenue":null,"mechanism":"Viberzi works by activating the mu-opioid receptor in the gut to slow down bowel movements and reduce diarrhea."},{"drug_id":"chlordiazepoxide","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlordiazepoxide Hydrochloride","generic_name":"CHLORDIAZEPOXIDE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Benzodiazepine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clidinium","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Librax","generic_name":"CLIDINIUM","company_name":"Roche","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"dicycloverine","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bentyl","generic_name":"dicycloverine","company_name":"Forest Labs Inc","drug_phase":"marketed","molecular_target":"Histamine H2 receptor","drug_class":"Anticholinergic","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"linaclotide","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Linzess","generic_name":"LINACLOTIDE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Heat-stable enterotoxin receptor","drug_class":"Guanylate Cyclase-C Agonist [EPC]","quality_score":57,"revenue":null,"mechanism":"Linzess works by activating the heat-stable enterotoxin receptor to increase fluid secretion in the intestines."},{"drug_id":"linaclotide","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Linzess","generic_name":"LINACLOTIDE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Heat-stable enterotoxin receptor","drug_class":"Guanylate Cyclase-C Agonist [EPC]","quality_score":57,"revenue":null,"mechanism":"Linzess works by activating the heat-stable enterotoxin receptor to increase fluid secretion in the intestines."},{"drug_id":"methylhomatropine","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hycodan","generic_name":"METHYLHOMATROPINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"","drug_class":"methylhomatropine","quality_score":54,"revenue":null,"mechanism":"Hycodan works by affecting the nervous system to reduce cough and relieve symptoms of irritable bowel syndrome and peptic ulcer."},{"drug_id":"xifaxan","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xifaxan","company_name":"Children's Hospital Los Angeles","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"alosetron","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotronex","generic_name":"ALOSETRON","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A","drug_class":"Serotonin-3 Receptor Antagonist","quality_score":66,"revenue":null,"mechanism":"Lotronex works by blocking serotonin receptors in the gut to slow down bowel movements."},{"drug_id":"linzess","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linzess","company_name":"TriHealth Inc.","drug_phase":"discontinued","molecular_target":"Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"linzess","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linzess","company_name":"TriHealth Inc.","drug_phase":"discontinued","molecular_target":"Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dicyclomine","indication_name":"Functional bowel/irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DICYCLOMINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic receptors","drug_class":"Antispasmodic and anticholinergic (antimuscarinic) agent","quality_score":55,"revenue":null,"mechanism":"Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract via a dual mechanism: anticholinergic effects at acetylcholine receptors and direct smooth muscle relaxation."},{"drug_id":"lubiprostone","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amitiza","generic_name":"LUBIPROSTONE","company_name":"Sucampo Pharma Llc","drug_phase":"marketed","molecular_target":"Chloride channel protein 2","drug_class":"Chloride Channel Activator [EPC]","quality_score":65,"revenue":null,"mechanism":"Amitiza works by activating chloride channels in the intestines, increasing fluid secretion and promoting bowel movements."},{"drug_id":"tegaserod","indication_name":"Irritable bowel syndrome characterized by constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zelnorm","generic_name":"TEGASEROD","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Serotonin-4 Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"homatropine","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Homatropin","generic_name":"homatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"methscopolamine","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylscopolamine","generic_name":"METHSCOPOLAMINE","company_name":"Fougera Pharms","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"rifaximine","indication_name":"Irritable bowel syndrome with diarrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rifaximine","company_name":"Ain Shams University","drug_phase":"phase_2","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hyoscyamine","indication_name":"Irritable Bowel Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"scopolamin","indication_name":"Irritable bowel syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":23,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04905524","title":"Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)","phase":"NA","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Viome","has_results":false},{"nct_id":"NCT05611606","title":"Welfare Benefits in Functional Somatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":9656,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05811663","title":"Health Care Use and Costs of Functional Somatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":9656,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03131414","title":"The IMAGINE-SPOR CIHR Chronic Disease Network","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Hamilton Health Sciences Corporation","has_results":false},{"nct_id":"NCT06006715","title":"Psychiatric Disorders and Functional Somatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":7493,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT05631860","title":"Psychological Risk Factors for Functional Somatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":7493,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05340400","title":"The Prevalence and Risk Factors of Irritable Bowel Syndrome Among Adults","phase":"","overall_status":"COMPLETED","enrollment_count":5500,"lead_sponsor_name":"University of Aleppo","has_results":false},{"nct_id":"NCT07261826","title":"Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Chen QiYi","has_results":false},{"nct_id":"NCT04462900","title":"Evaluate the Safety of Linaclotide in IBS-C Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":3028,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04817683","title":"Study on the Relationship Between Mobile Phone Addiction and Functional Gastrointestinal Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Second Affiliated Hospital of Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT02955316","title":"Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT05144594","title":"Direct Medical Costs Associated With Negative Diagnosis of IBS.","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Region Örebro County","has_results":false},{"nct_id":"NCT05144581","title":"Treatment of IBS in Primary Health Care.","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Region Örebro County","has_results":false},{"nct_id":"NCT03471728","title":"Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)","phase":"","overall_status":"COMPLETED","enrollment_count":2475,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03824821","title":"Assessing Associations Between IBS Symptoms, Nutrition and QoL in IBS Patients Using a Questionnaire","phase":"","overall_status":"COMPLETED","enrollment_count":2076,"lead_sponsor_name":"Wageningen University","has_results":false},{"nct_id":"NCT05795049","title":"Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT04918329","title":"Functional Digestive Disorders Observatory","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT00765999","title":"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1559,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT01553591","title":"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1282,"lead_sponsor_name":"Furiex Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT01553747","title":"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1146,"lead_sponsor_name":"Furiex Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT06610149","title":"A Novel Probiotic Mixture in Adults With IBS","phase":"NA","overall_status":"COMPLETED","enrollment_count":1098,"lead_sponsor_name":"University of Bari","has_results":false},{"nct_id":"NCT07033936","title":"Prevalence of Irritable Bowel Syndrome Among Egyptian Medical Students","phase":"","overall_status":"COMPLETED","enrollment_count":1093,"lead_sponsor_name":"Zagazig University","has_results":false},{"nct_id":"NCT03549143","title":"Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Abbott","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT04993989","title":"A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":843,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02590432","title":"An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":828,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT01130272","title":"Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":807,"lead_sponsor_name":"Furiex Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT05754190","title":"Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Brown University","has_results":false},{"nct_id":"NCT02612649","title":"Special Drug Use Surveillance of Irribow in Female Patients","phase":"","overall_status":"COMPLETED","enrollment_count":793,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT02559206","title":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06117865","title":"Digital Treatment of Irritable Bowel Syndrome (IBS)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":728,"lead_sponsor_name":"Haukeland University Hospital","has_results":false},{"nct_id":"NCT03573908","title":"A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":614,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06900491","title":"Irritable Bowel Syndrome Regional Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT01714843","title":"A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":559,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03459482","title":"Endpoint Determination Study Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":556,"lead_sponsor_name":"Biomerica","has_results":false},{"nct_id":"NCT06788444","title":"Efficacy of Esketamine for Patients With Irritable Bowel Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":552,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT03931785","title":"A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Ironwood Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02822677","title":"A Cross-sectional Study on IBS Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions","phase":"","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"Hong Kong Baptist University","has_results":false},{"nct_id":"NCT06171126","title":"Donor Selection for Faecal Microbiota Transplantation in Irritable Bowel Syndrome","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Haukeland University Hospital","has_results":false},{"nct_id":"NCT02316899","title":"Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT05740306","title":"Irritable Bowel Syndrome Overlaping Celiac Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Centre of Postgraduate Medical Education","has_results":false},{"nct_id":"NCT04270487","title":"The DOMINO Trial: Diet Or Medication in Irritable Bowel syNdrOme","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":472,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06002516","title":"RELIEF-pathway in Patients With Upper Abdominal Pain","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":471,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05810805","title":"Measurement and Analysis of Gas Composition in Digestive Tract","phase":"","overall_status":"UNKNOWN","enrollment_count":460,"lead_sponsor_name":"Xiuli Zuo","has_results":false},{"nct_id":"NCT05730491","title":"Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children","phase":"NA","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT03150212","title":"Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype","phase":"NA","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"Lesaffre International","has_results":false},{"nct_id":"NCT04665271","title":"Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS","phase":"NA","overall_status":"COMPLETED","enrollment_count":453,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04691544","title":"Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University Hospital of North Norway","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}